Global Direct-to-Consumer Laboratory Testing Market Size to grow by USD 10.09 billion in 2030.

Press Release

The Global Direct-to-Consumer (DTC) Laboratory Testing Market is projected to grow from USD 3.02 billion in 2021 to USD 10.09 billion by 2030 at a CAGR of 26% during the forecast period.

DTC laboratory testing, also known as direct access testing, allows patients to order tests directly from a laboratory without going through their doctor. These test findings can be used to track a current health state, identify an undetected medical problem, or provide information on personal health characteristics. DTC laboratory testing is a significant aspect of ongoing efforts to improve people's engagement in their healthcare, and the accuracy and accessibility of the results are critical. Professionals in the laboratory play a crucial role in this process.  

The COVID-19 pandemic, which was triggered by the severe acute respiratory disease CoV-2, posed an unexpected worldwide challenge, reshaping DTC testing innovation exercises. However, demand for DTC laboratory testing has increased as a result of the epidemic, and it is projected to continue to grow as more people become familiar with the method. Furthermore, one of the primary factors boosting market demand in the post-COVID-19 era is the rising occurrence of infectious disorders. As with other highly contagious illnesses, the COVID-19 outbreak has prompted the quick development and acceptance of DTC testing as part of the vital response plan, accelerating the direct-to-consumer laboratory testing business.

                           Request Free Sample To Learn More About This Report

In the DTC laboratory testing sector, smartphone-based healthcare services are becoming increasingly popular. For genetic decoding, a combination of artificial intelligence (AI) and cloud computing is being used to provide services like personalized health management. Cloud computing is assisting in the storage and management of personal genetic analysis data. This factor is expected to propel market growth in the globe during the forecast period. Moreover, market participants and telecommunication firms are expected to develop partnerships to assist people keep informed about their health by transmitting lab results directly to their phones.  

Patients who want information on their health state and illness risk, heritage, and their body's projected response to various prescriptions based on their genotype can use DTC testing, which is an interesting addition to the standard healthcare paradigm. The benefits of DTC laboratory testing are appealing and propelling the market. In the traditional concept of laboratory testing in healthcare, the patient must first recognize the need to see a doctor. It can be stressful for patients to wait for test results and interpretive data from their doctors. Understandably, consumers are ready for a new healthcare paradigm that offers greater convenience and detailed diagnostic data without the need for lengthy procedure         

North America is the largest market for DTC laboratory testing during the forecast period due to the increased prevalence of lifestyle-related and contagious diseases. The increased prevalence of infectious diseases, combined with government monitoring on promoting the quality and accuracy of laboratories doing DTC, is creating significant revenue streams in this region. 

The Asia Pacific DTC laboratory testing market is expected to grow at a high rate during the forecast period. Prospects have been boosted by the urgent need for user-friendly diagnostics and the growing need for consumer-driven genetic testing. The rise of the DTC laboratory testing market is likely to be fueled by an increase in government initiatives to encourage better, user-friendly diagnostics and genetic research in countries across Asia.  

                           Request Free Sample To Learn More About This Report

KEY INDUSTRY DEVELOPMENTS:    

In April 2019, Living DNA changed its ancestry platform to deliver more understandable findings and new capabilities. The company's product portfolio was improved as a result of this introduction.

In February 2019, Mapmygenome™ and Lucid Diagnostics cooperated to improve cancer prevention and tailored therapy by merging genomics and pathology test services. The company's market position was strengthened as a result of this strategic action.

Read More Details On This Report: https://extrapolate.com/Healthcare-Medical-Devices-Biotechnology/direct-to-consumer-laboratory-testing-market/25781